FILTER
FILTERED INTERVIEW RESULTS
Jeff Parshley
CORPORATE CONSULTANT, SRK CONSULTING
"Through our association with the University of Nevada, Reno, we are making great efforts to attract skilled graduates into the mining industry and into SRK, since there is currently a large gap in the market."
Mark Bristow
PRESIDENT AND CEO, BARRICK GOLD
Mark Bristow spoke with GBR about Barrick’s global operations and sustainability philosophy.
Rich Nolan
PRESIDENT AND CEO, NATIONAL MINING ASSOCIATION
The National Mining Association explains how the US is encouraging mining in order to ensure national demand for in critical minerals as well as traditional metals.
Ewan Downie
CEO, I-80 GOLD CORP
i-80 Gold Corp. is a gold producer and developer with a wide portfolio of advanced-stage gold projects in Nevada.
Keith Jones
GENERAL MANAGER, SMALL MINE DEVELOPMENT
Small Mine Development explains its service offering and gives insights about new mining methods.
Greg Walker
EXECUTIVE MANAGING DIRECTOR, NEVADA GOLD MINES
Nevada Gold Mines explains the rationale behind the creation of the joint venture between Barrick and Newmont and analyzes the potential of its assets.
Tyre Gray
PRESIDENT, NEVADA MINING ASSOCIATION (NVMA)
The Nevada Mining Association explains the current state of mining in the State and how the association advocates for a better general understanding of the sector.
Roel Schaapveld
CEO, INTERNA TECHNOLOGIES
InteRNA Technologies explains the promise of microRNA therapeutics.
Paula Brown Stafford
PRESIDENT & CEO, NOVAN
Novan explains its vision to be the world’s leading nitric oxide-based science, technology and clinical translation company.
Dr. Donald Gerson
COO & CO-FOUNDER, SAUDIVAX
SaudiVax provides an insight into the nascent biotech industry in Saudi Arabia.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
